Immune checkpoint inhibitors or anti-claudin 18.2 antibodies? A network meta-analysis for the optimized first-line therapy of HER2-negative gastric cancer.

ABSTRACT:

Background

Multiple anti-programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitors and zolbetuximab, an anti-claudin 18.2 antibody, have shown efficacy in the first-line treatment of HER2-negative gastric cancers. How to choose the best regimen remains an unsolved question.

Objectives

We aimed to conduct a comparative analysis of the therapeutic advantages between immunotherapy and anti-claudin-18.2-targeted therapies in the first-line treatment of HER2-negative, unresectable, or metastatic gastric cancers.

Design

Network meta-analysis was employed to systematically compare efficacy and safety data derived from various clinical trials.

Data sources and methods

We included phase III randomized controlled trials in PubMed, Embase, Web of Scie

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC10868489 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature